Key features and details
- Purity: > 70% HPLC
- Suitable for: Blocking
Product nameRanBP2 peptide
See all RanBP2 proteins and peptides
Purity> 70 % HPLC.
Peptides are analyzed by Reverse-Phase HPLC (RP-HPLC) in order to determine purity. Identities are confirmed by MALDI-MS.
Our Abpromise guarantee covers the use of ab4939 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
This peptide may be used for neutralization and control experiments with the polyclonal antibody that reacts with this product and human RanBP 2, catalog ab2938. Using a solution of peptide of equal volume and concentration to the corresponding antibody will yield a large molar excess of peptide (~ 70-fold) for competitive inhibition of antibody-protein binding reactions.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Reconstitution>95% pure, lyophilized synthetic peptide. Reconstitute with 0.1 ml of distilled water.
- 358 kDa nucleoporin
- E3 SUMO-protein ligase RanBP2
FunctionE3 SUMO-protein ligase which facilitates SUMO1 and SUMO2 conjugation by UBE2I. Involved in transport factor (Ran-GTP, karyopherin)-mediated protein import via the F-G repeat-containing domain which acts as a docking site for substrates. Could also have isomerase or chaperone activity and may bind RNA or DNA. Component of the nuclear export pathway. Specific docking site for the nuclear export factor exportin-1.
PathwayProtein modification; protein sumoylation.
Involvement in diseaseDefects in RANBP2 are the cause of susceptibility to encephalopathy acute necrotizing type 1 (ANE1) [MIM:608033]. A rapidly progressive encephalopathy manifesting in susceptibile individuals with seizures and coma. It can occur within days in otherwise healthy children after common viral infections such as influenza and parainfluenza, without evidence of viral infection of the brain or inflammatory cell infiltration. Brain T2-weighted magnetic resonance imaging reveals characteristic symmetric lesions present in the thalami, pons and brainstem.
Sequence similaritiesContains 1 PPIase cyclophilin-type domain.
Contains 4 RanBD1 domains.
Contains 8 RanBP2-type zinc fingers.
Contains 1 TPR repeat.
DomainContains F-X-F-G repeats.
modificationsPolyubiquitinated by PARK2, which leads to proteasomal degradation.
Cellular localizationNucleus > nuclear pore complex. Cytoplasmic filaments.
- Information by UniProt
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab4939 has not yet been referenced specifically in any publications.